Cargando…
Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
PURPOSE: Real-world data may provide insight into relationships between high triglycerides (TG), a modifiable cardiovascular (CV) risk factor, and increased heart failure (HF) risk. PATIENTS AND METHODS: This retrospective administrative claims analysis included statin-treated patients aged ≥45 year...
Autores principales: | Toth, Peter P, Philip, Sephy, Hull, Michael, Granowitz, Craig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900310/ https://www.ncbi.nlm.nih.gov/pubmed/31824165 http://dx.doi.org/10.2147/VHRM.S221289 |
Ejemplares similares
-
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020) -
Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2019) -
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018) -
Calcium of 19mg/dL and Yet Asymptomatic
por: Naqvi, Syeda, et al.
Publicado: (2021) -
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)